Inotuzumab ozogamicin is a monoclonal antibody-drug conjugate (ADC) used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is a targeted therapy, meaning it is designed to specifically target cancer cells. It works by delivering an anti-cancer drug directly to the cancer cells, which helps to reduce the risk of damage to healthy cells. It is given as an intravenous (IV) infusion once every 3 weeks. Common side effects include low white blood cell counts, nausea, fever, headache, and infection.
Inotuzumab ozogamicin, sold under the brand name Besponsa, is a medication used to treat a specific type of leukemia. Here's a breakdown of what you should know:
What is it for?
- Inotuzumab ozogamicin targets relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults.
- Relapsed leukemia means the cancer has come back after treatment.
- Refractory leukemia means the cancer did not respond well to initial treatment.
- B-cell precursor ALL is a type of blood cancer that affects immature B-cells, a type of white blood cell.
How does it work?
Inotuzumab ozogamicin is a type of drug called an antibody-drug conjugate (ADC). It works in two steps:
- Antibody targets leukemia cells: The medication has an antibody part that binds to a specific protein (CD22) found on the surface of B-cell leukemia cells. This targeted approach helps deliver the medication directly to cancer cells.
- Cytotoxic agent destroys cells: The antibody is linked to a cytotoxic agent (ozogamicin), a potent cell-killing toxin. Once attached to the leukemia cell, the toxin is released and works to destroy the cancer cell.
How is it administered?
Inotuzumab ozogamicin is given by intravenous infusion (IV), meaning it's injected into a vein typically over a period of time.
Important Considerations:
- Inotuzumab ozogamicin can cause serious side effects, including:
- Hepatotoxicity (liver damage): This can be life-threatening and requires close monitoring.
- Neutropenia (low white blood cell count): This increases the risk of infection.
- Neurologic effects: These may include confusion, dizziness, and neuropathy (tingling or numbness).
- Inotuzumab ozogamicin is not for everyone. Your doctor will consider your medical history and other factors to determine if it's the right treatment for you.
- It's important to talk to your doctor about all your medical conditions and medications before taking inotuzumab ozogamicin.
Additional Resources:
- Inotuzumab ozogamicin prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf
- National Cancer Institute: https://www.cancer.gov/types/leukemia/hp